The study is evaluating graphene-based brain–computer interfaces (BCIs) in human patients, marking the world’s first clinical study to assess a graphene device in direct contact with the human nervous system. This technology, developed at ICN2, has already shown promising initial results in both safety and its ability to detect and stimulate neuronal activity.